Toutes les études
Actif, mais pas en recrutementPHASE3INTERVENTIONNEL

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

This research is looking into a new medicine called Efruxifermin for liver conditions known as NAFLD/MASLD (fatty liver disease) and NASH/MASH (a more serious type of fatty liver disease). The main goal is to check how safe this medicine is and if people can tolerate it well when compared to a placebo, which is a dummy medicine containing no active drug. This is a Phase 3 study, meaning it’s a big, later-stage trial to confirm the medicine's effects. We’re inviting adults aged 18 to 80 who have been diagnosed with these liver conditions, often linked to other health issues like obesity or diabetes, to take part. The study aims to help us understand if Efruxifermin could be a future treatment option.

En un coup d'œil

Statut
Actif, mais pas en recrutement
Phase
PHASE3
Sponsor
Akero Therapeutics, Inc
Objectif d'inscription
700
Démarrer
10 Nov 2023
Achèvement estimé
19 Jun 2026

De quoi parle cette étude ?

This study is about a new medicine called Efruxifermin, and it's being tested for people who have certain liver conditions. These conditions are often called NAFLD/MASLD, which stands for non-alcoholic fatty liver disease, and NASH/MASH, which is a more advanced type of fatty liver disease. Essentially, these conditions mean there's too much fat in the liver, which can sometimes lead to inflammation and damage. The 'non-alcoholic' part means it's not caused by drinking too much alcohol.

The main purpose of this study is to see how safe Efruxifermin is and if people can take it without too many problems. We're also comparing it to a 'placebo', which looks exactly like the study medicine but doesn't contain any active drug. This helps us understand if any changes are truly due to the new medicine or if they might happen anyway. This type of study is called a Phase 3 trial, which means it's a large and important step in checking if a new medicine could eventually be made available to everyone.

By taking part, you could help doctors learn more about these liver conditions and whether Efruxifermin could be a helpful treatment in the future. We're looking for individuals who have been diagnosed with NAFLD/MASLD or NASH/MASH, often alongside other health issues like being overweight, having high blood pressure, or diabetes. Your involvement could make a real difference in advancing medical knowledge and helping others with similar conditions.

Points clés

  • The study is for adults with fatty liver conditions (NAFLD/MASLD or NASH/MASH).
  • It's testing a new medicine, Efruxifermin, against a dummy medicine (placebo).
  • The main aim is to check the medicine's safety and how well people tolerate it.
  • La participation implique des visites régulières à la clinique pour des contrôles de santé et des tests.
  • Your involvement could help develop future treatments for liver disease.

Qui peut être éligible ?

To be part of this study, you need to be an adult between 18 and 80 years old. You should also have either NAFLD/MASLD or NASH/MASH, which are liver conditions. Often, people with these liver conditions also have other health issues like being overweight, having high blood pressure, or diabetes. If you've been in a previous Akero study, there's a special option for you to join an extended part of this trial.

There are also some reasons why you might not be able to join. For example, if your liver problems are caused by something else, like drinking too much alcohol, other long-term illnesses, or certain medications. Also, if you have Type 1 diabetes, or your Type 2 diabetes isn't well-controlled, you might not be suitable for this study.

The research team will carry out checks to make sure this study is right for you and safe for you to take part. They will explain everything clearly, and you'll have the chance to ask any questions you have.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous entre 18 et 80 ans ?
  2. Have you been told you have NAFLD/MASLD or NASH/MASH?
  3. Do you have health conditions like obesity, high blood pressure, or Type 2 diabetes?
  4. Do you have any other liver conditions that aren't NAFLD/MASLD or NASH/MASH?
  5. Do you have Type 1 diabetes, or poorly controlled Type 2 diabetes?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part, you'll be given either the new medicine, Efruxifermin, or a placebo (a dummy medicine) throughout the study. Neither you nor your study doctor will know which one you're receiving. You'll need to attend clinic visits regularly for health checks, blood tests, and other assessments to monitor your health and how the medicine is affecting you. The total duration of your involvement in the study, including all visits and follow-up, will be fully explained by the research team.

Risques et avantages potentiels

Taking part in a study like this might offer potential benefits, such as receiving a new investigational treatment or being closely monitored by medical professionals. However, there are also potential risks, as the new medicine could cause side effects, some of which might not be known yet. The research team will discuss all known risks and benefits with you in detail. Remember, your participation is completely voluntary, and you have the right to withdraw from the study at any time without affecting your medical care.

Locations (211)

  • Akero Clinical Study Site
    Code postal vérifié
    Birmingham, États-Unis
  • Akero Clinical Study Site
    Code postal vérifié
    Chandler, United States
  • Akero Clinical Study Site
    Code postal vérifié
    Flagstaff, United States
  • Akero Clinical Study Site
    Code postal vérifié
    Peoria, États-Unis
  • Akero Clinical Study Site
    Code postal vérifié
    Tucson, États-Unis
  • Akero Clinical Study Site
    Code postal vérifié
    Tucson, États-Unis
  • Akero Clinical Study Site
    Code postal vérifié
    Conway, United States
  • Akero Clinical Study Site
    Code postal vérifié
    Jonesboro, United States
  • Akero Clinical Study Site
    Code postal vérifié
    Little Rock, États-Unis
  • Akero Clinical Study Site
    Code postal vérifié
    North Little Rock, United States
  • Akero Clinical Study Site
    Code postal vérifié
    Chula Vista, United States
  • Akero Clinical Study Site
    Code postal vérifié
    Coronado, United States

Questions fréquentes

What are NAFLD/MASLD and NASH/MASH?

These are liver conditions where too much fat builds up in the liver. NASH/MASH is a more serious type where the liver also becomes inflamed and damaged.

Qu'est-ce qu'un placebo ?

A placebo is a dummy medicine that looks exactly like the study drug but doesn't contain any active ingredients. It helps researchers see if the real medicine is actually working.

Saurai-je si je reçois le vrai médicament ou le placebo ?

No, during the main part of the study, neither you nor your study doctor will know whether you are receiving Efruxifermin or the placebo. This helps make the study results fair.

Is this medicine available for everyone yet?

No, Efruxifermin is an 'investigational' medicine, which means it's still being studied and is not yet approved or available for general use outside of clinical trials.

Et si je change d'avis concernant ma participation ?

Vous êtes libre de quitter l'étude à tout moment, pour n'importe quelle raison, sans que cela n'affecte vos soins médicaux habituels.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.